Close Menu

NEW YORK – Fulgent Genetics reported after the close of the market on Monday a 44 percent increase in first quarter revenues driven by a large jump in billable test numbers. The firm also withdrew its 2020 full-year revenue guidance.

For the three months ended March 31, Fulgent posted revenues of $7.8 million versus $5.4 million in the same quarter last year. The firm said it delivered 13,163 billable genetic tests during Q1, a 75 percent increase year over year.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.